Imagen de Portada

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Alba López‐Bravo, Ane Mínguez‐Olaondo, Candela Nieves‐Castellanos, Marta Ruibal‐Salgado, Noemí Morollón Sánchez‐Mateos, María Pilar Navarro‐Pérez, Alicia Alpuente, Marta Torres‐Ferrús, Jésica García‐Ull, Ana Gago‐Veiga, David García‐Azorín, Alicia González‐Martínez, Álvaro Sierra, Sonia Santos‐Lasaosa
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Headache: The Journal of Head and Face Pain
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
por: Anna de Dios, et al.
Publicado: (2024)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
por: Julia Peris‐Subiza, et al.
Publicado: (2025)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
por: Alicia Alpuente, et al.
Publicado: (2026)

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
por: María Clara García‐Castillo, et al.
Publicado: (2026)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
por: Joaquín Borrás‐Blasco, et al.
Publicado: (2025)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
por: Jennifer Robblee, et al.
Publicado: (2024)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
por: Marta Pascual‐Mato, et al.
Publicado: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
por: Andrea M. Kuczynski, et al.
Publicado: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
por: Kara S. Graves, et al.
Publicado: (2026)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
por: Samuel K. Peasah, et al.
Publicado: (2024)

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine
por: Christoph T. Berger, et al.
Publicado: (2026)

Long‐term evolution of white and gray matter structural properties in migraine
por: Álvaro Planchuelo‐Gómez, et al.
Publicado: (2025)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
por: Yunzhu Tang, et al.
Publicado: (2025)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
por: Alex Jaimes, et al.
Publicado: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
por: Tzu‐Hsuan Su, et al.
Publicado: (2024)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
por: Muneto Tatsumoto, et al.
Publicado: (2024)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
por: Irina Krikova, et al.
Publicado: (2024)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
por: Jessica Ailani, et al.
Publicado: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
por: Graham A. McLeod, et al.
Publicado: (2025)

Serum levels of autotaxin reveal its role as a novel biomarker of migraine
por: Alberto Ouro, et al.
Publicado: (2025)

A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross‐sectional headache registry study in youth
por: Carlyn Patterson Gentile, et al.
Publicado: (2024)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
por: Eric A. Kaiser, et al.
Publicado: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
por: Rikki Mangrum, et al.
Publicado: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
por: Yunus Emre Meydanal, et al.
Publicado: (2025)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
por: Alex Harlan, et al.
Publicado: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
por: David Croteau, et al.
Publicado: (2026)

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
por: Chay Ngee Lim, et al.
Publicado: (2025)

Evaluating associations of migraine‐related vertigo
por: Nazia Karsan, et al.
Publicado: (2025)

Afterimage duration differs for migraine with or without aura
por: Florian Rimmele, et al.
Publicado: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
por: Rebecca Erwin Wells, et al.
Publicado: (2024)

Useful considerations for treating migraine in patients with autism
por: Sinifunanya E. Nwaobi
Publicado: (2026)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
por: Gabriel Camargo de Oliveira, et al.
Publicado: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
por: Shuu‐Jiun Wang, et al.
Publicado: (2024)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
por: Inga Zalia Tummoszeit, et al.
Publicado: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
por: Chia‐Chun Chiang, et al.
Publicado: (2024)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
por: Zoe Tasma, et al.
Publicado: (2025)

Counting the cost: How migraine shapes lives and economies
por: Risako Shirane, et al.
Publicado: (2025)

Cardiovascular risk and triptan usage among patients with migraine
por: Ido Peles, et al.
Publicado: (2025)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
por: Amy A. Gelfand
Publicado: (2024)

Cognitive and emotional mechanisms underlying migraine quality of life
por: Shiri Shinan‐Altman, et al.
Publicado: (2026)